levodopa has been researched along with tolcapone in 134 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 70 (52.24) | 18.2507 |
| 2000's | 43 (32.09) | 29.6817 |
| 2010's | 15 (11.19) | 24.3611 |
| 2020's | 6 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brannan, T; Martínez-Tica, J; Yahr, MD | 1 |
| Acquas, E; Carboni, E; Da Prada, M; de Ree, RH; Di Chiara, G | 1 |
| Männistö, PT; Tuomainen, P; Tuominen, RK | 1 |
| Andersson, Y; Antoni, G; Bjurling, P; Hartvig, P; Långström, B; Tedroff, J | 1 |
| Da Prada, M | 1 |
| Maj, J; Rogóz, Z; Skuza, G; Sowińska, H; Superata, J | 1 |
| Colzi, A; Da Prada, M; Zürcher, G | 1 |
| Abe, T; Saheki, M; Takahashi, S; Tohgi, H; Tsukamoto, Y; Yamazaki, K | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Fukazawa, H; Funaki, T; Kuruma, I; Onodera, H; Tagami, C; Tsukamoto, Y; Ushiyama, N | 1 |
| Da Prada, M; Napolitano, A; Zürcher, G | 1 |
| Lang, A; Männistö, PT; Rauhala, P; Vasar, E | 1 |
| Gordin, A; Kaakkola, S; Männistö, PT | 1 |
| Fernandes, MH; Soares-da-Silva, P | 1 |
| Himori, N; Mishima, K | 1 |
| Gervason-Tournier, CL; Hommel, M; Limousin, P; Perret, JE; Pollak, P | 1 |
| Männistö, PT; Törnwall, M | 1 |
| Amantea, MA; Bravi, D; Chase, TN; Cora-Locatelli, G; Mouradian, MM; Roberts, JW | 1 |
| Da Prada, M; Dingemanse, J; Zürcher, G | 1 |
| Da Prada, M; Dingemanse, J; Jorga, K; Schmitt, M; Sedek, G; Van Brummelen, P; Zürcher, G | 1 |
| Dubuis, R; Limousin, P; Perret, JE; Pfefen, JP; Pollak, P; Tournier-Gervason, CL | 1 |
| Dingemanse, J; Fotteler, B; Jorga, K; Nielsen, T; Sedek, G; van Brummelen, P; Zürcher, G | 1 |
| Adler, CH; Chernik, DA; Dorflinger, EE; Hilaire, MS; Kurth, MC; LeWitt, P; Singer, C; Waters, C; Yoo, K | 1 |
| Chan, GL; Doudet, DJ; Holden, JE; Morrison, KS; Ruth, TJ; Wyatt, RJ | 1 |
| Hattori, Y; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Narabayashi, H; Tohgi, H; Tsukamoto, Y; Yamamoto, M; Yanagisawa, N; Yokochi, M | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Schmitt, M; Zürcher, G | 1 |
| Agid, Y; Destée, A; Durif, F; Montastruc, JL; Pollak, P | 1 |
| Bailey, P; Deptula, D; Dorflinger, E; Kurth, M; LeWitt, P; Pedder, S; Shulman, LM; Waters, CH | 2 |
| Männistö, PT | 1 |
| Aitken, JW; Fotteler, B; Jorga, KM; Nielsen, T; Sedek, G; Zürcher, G | 1 |
| Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G | 2 |
| Calne, DB; Chan, GL; Doudet, DJ; Holden, JE; Morrison, KS; Pate, BD; Ruth, TJ | 1 |
| Burgunder, JM; Dorflinger, E; Dupont, E; Findley, LJ; Olsson, JE | 1 |
| Burns, RS; Jorga, K; Leese, P; Schmitt, M; Sêdek, G | 1 |
| d'Agostini, F; Damsma, G; DaPrada, M; DeBoer, P; Heeringa, MJ | 1 |
| Budygin, EA; Gaĭnetdinov, RR; Mannisto, PT; Raevskiĭ, KS | 1 |
| Kulisevsky, J | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Sedek, G | 1 |
| Adler, CH; Kurth, MC | 1 |
| Goetz, CG | 2 |
| Jorga, KM | 1 |
| Dorflinger, E; Martin, W; Pedder, S; Rajput, AH; Saint-Hilaire, MH | 1 |
| Martínez-Martín, P; O'Brien, CF | 1 |
| Nutt, JG | 1 |
| Fernandez, HH; Friedman, JH | 1 |
| Adler, CH; Deptula, D; Dorflinger, E; Hauser, RA; Lew, MF; Marek, KL; O'Brien, C; Pedder, S; Singer, C; Yoo, K | 1 |
| Harper, J; Vieira, B | 1 |
| Dajani, EZ; Dajani, NE; Dayton, MT; Larsen, KR; Moore, JG | 1 |
| Rinne, UK; Ruottinen, HM | 1 |
| Guay, DR | 1 |
| Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M | 1 |
| Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL | 1 |
| Bornkessel, B | 1 |
| Ludin, HP | 1 |
| Jorga, KM; Nicholl, DJ | 1 |
| Fasth, KJ; Hartvig, P; Långström, B; Tedroff, J; Torstenson, R | 1 |
| Stacy, M | 1 |
| Bosch, A; Figueras, A; Pedrós, C; Sabaté, M | 1 |
| Ahlskog, JE | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 2 |
| Gainetdinov, R; Huotari, M; Männistö, PT | 1 |
| LeWitt, PA | 1 |
| Bernardi, G; Federici, M; Mercuri, NB | 1 |
| Kuhn, W; Müller, T; Peters, S; Przuntek, H; Schulz, D; Woitalla, D | 1 |
| Chernik, D; Dorflinger, E; Waters, C; Welsh, MD | 1 |
| Waters, C | 1 |
| Bonoma, RA; Iwuagwu, CU; Riley, D | 1 |
| Fotteler, B; Jorga, KM; Modi, M; Rabbia, M | 1 |
| Yanagisawa, N | 1 |
| Budygin, EA; Gaĭnetdinov, RR; Mannisto, P; Raevskiĭ, KS; Wightman, M | 1 |
| Dingemanse, J | 1 |
| Hubble, J; Kieburtz, K | 1 |
| Iwata, S; Kaseda, S; Nomoto, M | 1 |
| Chao, LY; Lee, SJ; Shan, DE; Yeh, SI | 1 |
| Gerlach, M; Kuhn, W; Lehnfeld, R; Riederer, P; Sontag, KH; Waldmeier, P; Xiao, AY | 1 |
| Gálvez-Jiménez, N; Hanson, MR | 1 |
| Baas, H; Harder, S; Kohnen, R; Loetsch, J; Selzer, R; Zehrden, F | 1 |
| Bonanni, L; Di Iorio, A; Iacono, D; Onofrj, M; Thomas, A | 1 |
| Doder, M; Hely, M; Koller, W; Lees, A | 1 |
| Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ | 1 |
| Haasio, K; Koponen, A; Nissinen, E; Penttilä, KE | 1 |
| Foley, P; Gerlach, M; Riederer, P | 1 |
| Blandini, F; Bono, G; Calandrella, D; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Riboldazzi, G; Samuele, A | 1 |
| Benabou, R; Waters, C | 1 |
| Stocchi, F | 1 |
| Aubin, N; Barneoud, P; Burnier, P; Caille, D; Carter, C; Charieras, T; Curet, O; Gardes, A; George, P; Jegham, S; Le Kim, A; Lolivier, J; Marc, C; Pandini, M; Perron, C; Puech, F; Scatton, B; Sontag, N | 1 |
| Takáts, A | 1 |
| Clarke, CE; Deane, KH; Spieker, S | 2 |
| Borges, N | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Comella, C; Widnell, KL | 1 |
| Kuhn, W; Müller, T | 1 |
| Leegwater-Kim, J; Waters, C | 1 |
| Lees, AJ; Oertel, WH; Ratziu, V; Tolosa, E | 1 |
| Pahwa, R | 1 |
| De Pandis, MF; Stocchi, F | 1 |
| Pirtosek, Z | 1 |
| Antonini, A; Canesi, M; Pezzoli, G; Zecchinelli, AL | 1 |
| Truong, DD | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Factor, S; Sethi, K; Watts, R | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Kaakkola, S | 1 |
| Askmark, H; Johansson, A; Lennernäs, H; Nyholm, D | 1 |
| Herrmann, L; Muhlack, S; Müller, T; Salmen, S | 1 |
| Bonifácio, MJ; Loureiro, AI; Palma, PN; Soares-da-Silva, P; Torrão, L; Wright, LC | 1 |
| Cardoso, MA; de Carvalho, KA; de Francisco, TM; de Oliveira Vilhena, R; Gasparetto, JC; Guimarães de Francisco, TM; Martins, CA; Pontarolo, R; Ribeiro, RP | 1 |
| Cao, L; Hao, H; Hao, K; Li, F; Liu, H; Qi, Q; Wang, H | 1 |
| Kudrin, VS; Kurina, AU; Pronina, TS; Ugrumov, MV | 1 |
| Katsaiti, I; Nixon, J | 1 |
| Baumann, A; Baumann, CR; Landolt, HP; Linnebank, M; Masneuf, S; Morawska, MM; Moreira, CG; Noain, D; Sommerauer, M | 1 |
| Artusi, CA; Fabbri, M; Imbalzano, G; Lopiano, L; Sarro, L | 1 |
| Buhmann, C; Classen, J; Eggert, K; Jost, WH; Kohl, Z; Outeiro, T; Reichmann, H; Tönges, L; Woitalla, D | 1 |
| Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P | 1 |
| Cagiada, M; Dideriksen, J; Hartmann-Petersen, R; Larsen, FB; Lindorff-Larsen, K; Stein, A | 1 |
| Barrière, G; Boulain, M; Chagraoui, A; Courtand, G; De Deurwaerdère, P; Fettah, A; Juvin, L; Khsime, I | 1 |
35 review(s) available for levodopa and tolcapone
| Article | Year |
|---|---|
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Topics: Animals; Behavior, Animal; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Dihydroxyphenylalanine; Humans; Levodopa; Microdialysis; Nitriles; Nitrophenols; Pentanones; Tolcapone; Tomography, Emission-Computed | 1994 |
COMT inhibition: a new treatment strategy for Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Influence of COMT inhibition on levodopa pharmacology and therapy.
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Topics: Antiparkinson Agents; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Volunteers | 1998 |
Extending levodopa action: COMT inhibition.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Pentanones; Tolcapone | 1998 |
COMT inhibition in the treatment of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Humans; Levodopa; Multicenter Studies as Topic; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
[Modern therapeutic possibilities in Parkinson disease].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Nitrophenols; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tolcapone | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
New drugs for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 2000 |
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Patient Selection; Tolcapone | 2000 |
[A prospect of treatment for Parkinson's disease in the 21st century].
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy; Forecasting; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Nitrophenols; Parkinson Disease; Quality of Life; Tolcapone | 2000 |
Issues important for rational COMT inhibition.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinsonian Disorders; Tolcapone | 2000 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tolcapone | 2001 |
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Dopamine Agents; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
The relevance of preclinical studies for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug Evaluation, Preclinical; Humans; Levodopa; Neuroprotective Agents; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 2003 |
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Prevention and treatment of motor fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Benzophenones; Dyskinesias; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Bromocriptine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Pergolide; Tolcapone | 2004 |
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Topics: Adenosine Triphosphate; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Chemical and Drug Induced Liver Injury; Half-Life; Humans; Levodopa; Liver; Mitochondria; Nitrophenols; Oxidative Stress; Parkinson Disease; Phosphorylation; Safety; Tolcapone | 2005 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
Tolcapone in the management of Parkinson's disease.
Topics: Animals; Benzophenones; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2006 |
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Topics: Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2006 |
Utility of tolcapone in fluctuating Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Periodicity; Severity of Illness Index; Tolcapone | 2006 |
'Bad guys' among the antiparkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Cholinergic Antagonists; Cognition; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Survival Rate; Tolcapone; Treatment Outcome | 2009 |
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 2009 |
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2010 |
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; Tolcapone; Treatment Outcome | 2018 |
Safety and efficacy of tolcapone in Parkinson's disease: systematic review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemical and Drug Induced Liver Injury; Humans; Levodopa; Liver Function Tests; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Tolcapone | 2021 |
[Relevance of COMT inhibitors in the treatment of motor fluctuations].
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Parkinson Disease; Tolcapone | 2022 |
39 trial(s) available for levodopa and tolcapone
| Article | Year |
|---|---|
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
Topics: Aged; Benzophenones; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 1993 |
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Topics: Adolescent; Adult; Aged; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Synergism; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease, Secondary; Placebos; Tolcapone | 1993 |
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
Topics: Adult; Benzophenones; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Levodopa; Male; Nitrophenols; Pharmacokinetics; Time Factors; Tolcapone; Volunteers | 1995 |
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Tolcapone | 1995 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
Topics: Aged; Benzophenones; Biotransformation; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Erythrocytes; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Tolcapone | 1996 |
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
Topics: Aged; Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitrophenols; Parkinson Disease; Placebos; Tolcapone; Treatment Outcome | 1997 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1997 |
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Topics: Adjuvants, Pharmaceutic; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Male; Nitrophenols; Reference Values; Tolcapone | 1997 |
Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
Topics: Antiparkinson Agents; Benzophenones; Bromocriptine; Drug Therapy, Combination; Drug Tolerance; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzophenones; Diarrhea; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Sickness Impact Profile; Tolcapone; Treatment Outcome | 1997 |
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Topics: Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Erythrocytes; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nervous System Diseases; Nitrophenols; Tolcapone | 1997 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone | 1997 |
Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone | 1997 |
Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
Topics: Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benzophenones; Biotransformation; Carbidopa; Cross-Over Studies; Drug Combinations; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Single-Blind Method; Tolcapone | 1997 |
[Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
Topics: Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzophenones; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Treatment Outcome | 1998 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Diarrhea; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
Topics: Aged; Antiparkinson Agents; Benzophenones; Canada; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Psychomotor Performance; Tolcapone; United States | 1998 |
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
Topics: Aged; Antiparkinson Agents; Benzophenones; Bromocriptine; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1999 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Tyrosine | 1999 |
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone | 1999 |
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
Tolcapone increases maximum concentration of levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Topics: Adaptation, Psychological; Adult; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Sick Role; Sickness Impact Profile; Tolcapone; Treatment Outcome | 2000 |
Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
Topics: Adult; Antiparkinson Agents; Benzophenones; Cross-Over Studies; Desipramine; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Hemodynamics; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
Topics: Aged; Antiparkinson Agents; Benzophenones; Biological Availability; Double-Blind Method; Female; Gait; Half-Life; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Topics: Aged; Area Under Curve; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
Topics: Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Pergolide; Quality of Life; Tolcapone; Treatment Outcome | 2001 |
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Prospective Studies; S-Adenosylhomocysteine; Tolcapone | 2006 |
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiparkinson Agents; Aspartate Aminotransferases; Benzophenones; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2007 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Residence Characteristics; Severity of Illness Index; Surveys and Questionnaires; Tolcapone; United States; Young Adult | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechols; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Pilot Projects; Self Report; Single-Blind Method; Sweden; Tolcapone; Tyrosine | 2012 |
60 other study(ies) available for levodopa and tolcapone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dopamine; Homovanillic Acid; Levodopa; Male; Nitrophenols; Rats; Rats, Inbred Strains; Tolcapone | 1992 |
Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Topics: Administration, Oral; Animals; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Caudate Nucleus; Dopamine; Drug Interactions; Extracellular Space; Levodopa; Male; Nitrophenols; Osmolar Concentration; Rats; Rats, Inbred Strains; Tetrodotoxin; Tolcapone | 1992 |
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Topics: Amidines; Animals; Benzophenones; Biogenic Monoamines; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Homovanillic Acid; Hypothalamus; Levodopa; Male; Methyldopa; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Inbred Strains; Tolcapone | 1992 |
Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Topics: Animals; Benserazide; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone; Tomography, Emission-Computed | 1991 |
Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease.
Topics: Animals; Antipsychotic Agents; Benzophenones; Catalepsy; Catechol O-Methyltransferase; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Levodopa; Male; Mice; Motor Activity; Nitrophenols; Nomifensine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Tolcapone | 1990 |
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
Topics: Animals; Benserazide; Benzophenones; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Electrochemistry; Erythrocytes; Half-Life; In Vitro Techniques; Levodopa; Male; Nitrophenols; Norepinephrine; Rats; Rats, Inbred Strains; Tolcapone; Tyrosine | 1990 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1995 |
Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Topics: Animals; Benserazide; Benzophenones; Biotransformation; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Half-Life; Injections, Intravenous; Levodopa; Male; Methylation; Nitrophenols; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Tissue Distribution; Tolcapone | 1995 |
Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Homovanillic Acid; Levodopa; Male; Methylation; Microdialysis; Neostriatum; Nitrophenols; Rats; Tolcapone | 1995 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Depression; Desipramine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Levodopa; Male; Motor Activity; Nitriles; Nitrophenols; Rats; Rats, Wistar; Swimming; Tolcapone | 1995 |
Role of monoamine oxidase and catechol-O-methyltransferase in the metabolism of renal dopamine.
Topics: Animals; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Culture Media; Dopamine; In Vitro Techniques; Kidney; Levodopa; Male; Monoamine Oxidase; Nitrophenols; Osmolar Concentration; Rats; Rats, Wistar; Tolcapone; Tropolone | 1994 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Synergism; Haloperidol; Kinetics; Levodopa; Male; Mice; Mice, Inbred C57BL; Nitrophenols; Tolcapone; Tyrosine | 1994 |
Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
Topics: Amidines; Amphetamine; Animals; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Clorgyline; Drug Interactions; Drug Synergism; Levodopa; Male; Methylation; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Wistar; Tolcapone | 1993 |
Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.
Topics: Animals; Benserazide; Benzophenones; Brain; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Homovanillic Acid; Humans; Levodopa; Male; Nitrophenols; Peripheral Nerves; Rats; S-Adenosylhomocysteine; S-Adenosylmethionine; Tolcapone | 1993 |
Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzophenones; Catechol O-Methyltransferase; Disease Models, Animal; Enzyme Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
New treatment for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzophenones; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
Topics: Amidines; Animals; Antiparkinson Agents; Benzophenones; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Female; Levodopa; Macaca mulatta; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Pregnancy; Pyridones; Rats; Tolcapone | 1998 |
Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Enzyme Inhibitors; Fluorine Radioisotopes; Levodopa; Macaca fascicularis; Monoamine Oxidase Inhibitors; Nitrophenols; Pentanones; Pilot Projects; Tolcapone; Tomography, Emission-Computed; Visual Cortex | 1997 |
[New methods in the pharmacotherapy of Parkinson disease].
Topics: Antiparkinson Agents; Benzophenones; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Tolcapone | 1996 |
[COMT inhibition with tolcapone].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Synergism; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1996 |
Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Levodopa; Male; Monoamine Oxidase Inhibitors; Motor Activity; Nitrophenols; Oxidopamine; Picolinic Acids; Rats; Rotation; Thiazoles; Tolcapone | 1997 |
[Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dopamine; Dopamine Agents; Drug Synergism; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Nitrophenols; Rats; Rats, Wistar; Tolcapone | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
New anti-parkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 1998 |
Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Confusion; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.
Topics: Animals; Benzophenones; Biological Transport; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Electrolytes; Enzyme Inhibitors; Female; Intestinal Mucosa; Intestinal Secretions; Intestines; Levodopa; Nitrophenols; Tolcapone | 1998 |
[Tolcapon potentiates the Levodopa effect].
Topics: Antiparkinson Agents; Benzophenones; Drug Synergism; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Tolcapone | 1998 |
[COMT inhibitors].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Topics: Animals; Antiparkinson Agents; Benzophenones; Carbon Radioisotopes; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Fluorine Radioisotopes; Levodopa; Macaca mulatta; Nitrophenols; Presynaptic Terminals; Tolcapone; Tomography, Emission-Computed | 1999 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Vitiligo | 1999 |
Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Haloperidol; Homovanillic Acid; Levodopa; Male; Microdialysis; Nitrophenols; Piperazines; Rats; Rats, Wistar; Time Factors; Tolcapone; Visual Cortex | 1999 |
Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons.
Topics: Animals; Benzophenones; Catechol O-Methyltransferase Inhibitors; Cells, Cultured; Dopamine; Dopamine Antagonists; Electrophysiology; Enzyme Inhibitors; GABA Antagonists; Glycine Agents; Levodopa; Male; Neurons; Nitrophenols; Organophosphorus Compounds; Parkinson Disease; Picrotoxin; Rats; Rats, Wistar; Strychnine; Substantia Nigra; Sulpiride; Synaptic Transmission; Tolcapone; Ventral Tegmental Area | 1999 |
Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Confusion; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Nitrophenols; Substance Withdrawal Syndrome; Tolcapone | 2000 |
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Clinical Trials, Phase II as Topic; Double-Blind Method; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Models, Theoretical; Multicenter Studies as Topic; Nitrophenols; Parkinson Disease; Population Surveillance; Randomized Controlled Trials as Topic; Tolcapone | 2000 |
[Pharmacological modulation of dopaminergic transmission in the rat striatum in vivo].
Topics: Animals; Benzophenones; Carrier Proteins; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Drug Interactions; Enzyme Inhibitors; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Microdialysis; Nerve Tissue Proteins; Nitrophenols; Piperazines; Rats; Rats, Wistar; Stereotyped Behavior; Synaptic Transmission; Tolcapone | 2000 |
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Levodopa; Male; Microdialysis; Nitriles; Nitrophenols; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Tolcapone | 2001 |
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Substance Withdrawal Syndrome; Tolcapone | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Disease Progression; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 2002 |
Effects of entacapone and tolcapone on mitochondrial membrane potential.
Topics: Animals; Benzophenones; Catechols; Levodopa; Male; Membrane Potentials; Mitochondria, Liver; Nitriles; Nitrophenols; Rats; Rats, Sprague-Dawley; Tolcapone | 2002 |
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Benzophenones; Blood Platelets; Catechols; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Retrospective Studies; Sex Characteristics; Tolcapone; Tyrosine; Up-Regulation | 2003 |
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Maze Learning; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; MPTP Poisoning; Nervous System Diseases; Nitrophenols; Oxazoles; Oxidopamine; Prefrontal Cortex; Quinolines; Rats; Rats, Sprague-Dawley; Serotonin; Stereotyped Behavior; Tolcapone; Tremor; Tyramine | 2004 |
[Treatment in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Clinical experience of tolcapone in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 2008 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric; Tolcapone; Treatment Outcome | 2014 |
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Benzophenones; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cell Survival; Cells, Cultured; Hepatocytes; Humans; Levodopa; Male; Membrane Potential, Mitochondrial; Models, Biological; Nitriles; Nitrophenols; Oxadiazoles; Rats, Wistar; Tolcapone | 2015 |
Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Topics: Benzophenones; Blood Chemical Analysis; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Nitriles; Nitrophenols; Quality Control; Reproducibility of Results; Tandem Mass Spectrometry; Tolcapone; Tyrosine | 2015 |
Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats.
Topics: Animals; Benzofurans; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Kinetics; Levodopa; Male; Metabolome; Methylation; Nitrophenols; Organ Specificity; Rats, Sprague-Dawley; Reproducibility of Results; Substrate Specificity; Tolcapone; Tyrosine | 2015 |
Missing proof of cooperative synthesis of dopamine by non-dopaminergic neurons.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzophenones; Catechol O-Methyltransferase Inhibitors; Coculture Techniques; Dopamine; Hypothalamus; Isotonic Solutions; Leucine; Levodopa; Male; Neurons; Nitrophenols; Rats, Wistar; Substantia Nigra; Tolcapone; Tyrosine 3-Monooxygenase | 2016 |
Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Dopamine Plasma Membrane Transport Proteins; Eating; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Parkinson Disease; Psychomotor Performance; Tolcapone; Vesicular Monoamine Transport Proteins | 2020 |
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone | 2022 |
Rare Catechol-
Topics: Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catecholamines; Levodopa; Proteasome Endopeptidase Complex; Tolcapone | 2023 |
Limiting Monoamines Degradation Increases L-DOPA Pro-Locomotor Action in Newborn Rats.
Topics: Animals; Animals, Newborn; Catechol O-Methyltransferase; Levodopa; Locomotion; Nialamide; Rats; Tolcapone | 2023 |